Autoimmune liver disease-related autoantibodies in patients with biliary atresia

Table 2 Prevalence profile of autoimmune liver disease in biliary atresia patients and non-biliary atresia controls n (%)

Variable	BA, n = 81	Non-BA, n = 88
		Other liver diseases1, n = 44	Healthy, n = 40	Total
PBC-related antibodies	15 (18.5)c	4 (9.1)	1 (2.5)	5 (5.7)
AMA-M2	1 (1.2)	0 (0)	0 (0)	0 (0)
Anti- BPO	12 (14.8)ac	2 (4.5)	0 (0)	2 (2.2)
Anti-Sp100	1 (1.2)	0 (0)	0 (0)	0 (0)
Anti-gp210	2 (2.5)	1 (2.3)	1 (2.5)	2 (2.2)
Anti-PML	3 (3.7)	1 (2.3)	0 (0)	1 (1.1)
AMA-M2 + anti-BPO	1 (1.2)	0 (0)	0 (0)	0 (0)
AMA-M2 + anti-BPO + anti-Sp100 + anti-PML	1 (1.2)	0 (0)	0 (0)	0 (0)
AIH-related antibodies	6 (7.4)	3 (6.8)	3 (7.5)	6 (6.8)
Anti-LKM-1	0 (0)	0 (0)	0 (0)	0 (0)
Anti-LC-1	5 (6.2)	3 (6.8)	3 (7.5)	6 (6.8)
Anti-SLA/LP	1 (1.2)	0 (0)	0 (0)	0 (0)
Anti-Ro-52	5 (6.2)	2 (4.5)	2 (5)	4 (4.5)

¹Choledochal cysts, transient cholestasis of unknown origin, and neonatal intrahepatic cholestasis caused by citrin deficiency were included as disease controls. AMA-M2 + M2-3E: combined the positivity to AMA-M2 and BPO; AMA-M2 + BPO + Sp100 + PML: Combined the positivity to AMA-M2, BPO, Sp100, and PML.

^cP < 0.05 vs non-BA;

^aP < 0.05 vs healthy controls. AIH: Autoimmune hepatitis; BA: Biliary atresia; PBC: Primary biliary cholangitis; LKM-1: Liver-kidney microsomal type 1; LC-1: Liver cytosolic antigen type 1.